Abstract
Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Current Molecular Medicine
Title:Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer
Volume: 14 Issue: 1
Author(s): P. Yang, S.-X. Liang, W.-H. Huang, H.-W. Zhang, X.-L. Li, L.-H. Xie, C.-W. Du and G.-J. Zhang
Affiliation:
Keywords: Apoptosis, chemokine (C-X-C motif) ligand 12 (CXCL12), CXC chemokine receptor types 4 (CXCR4), EMT (epithelial mesenchymal transition), shRNA, triple negative breast cancer, visceral organ specific metastases.
Abstract: Triple negative breast cancer is known for its visceral metastasis. We have found that CXCR4 is overexpressed in triple negative breast cancer and is associated with visceral metastasis. We further investigated whether CXCR4 is a prognostic factor affecting survival following visceral metastasis in breast cancer patients. Our results indicate that increased CXCR4 expression among breast cancer patients with visceral metastasis was positively correlated with poor overall survival (P<0.001). Silencing of CXCR4 was associated with a decrease in the tumorigenic properties of MDA-MB-231 breast cancer cells, caused reversion of EMT and suppression of MMP-9, increased apoptosis, and caused a reduced incidence of tumor lung metastasis in mice. These results are indicative of CXCR4 having a predictive role in patients with visceral metastasis and indicate that shRNA knock down of CXCR4 might be a novel therapeutic strategy to prevent breast cancer metastasis when CXCR4 is overexpressed.
Export Options
About this article
Cite this article as:
Yang P., Liang S.-X., Huang W.-H., Zhang H.-W., Li X.-L., Xie L.-H., Du C.-W. and Zhang G.-J., Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131121115656
DOI https://dx.doi.org/10.2174/1566524013666131121115656 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Docking Investigation on Bis (Nitro Indazolyl) Methanes; Synthesis and Antimicrobial Activity Towards Breast Cancer Applications
Letters in Organic Chemistry Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis
Current Medicinal Chemistry Current Status of Newer Carbapenems
Current Medicinal Chemistry Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Clostridium difficile Infection: Associations with Chemotherapy, Radiation Therapy, and Targeting Therapy Treatments
Current Medicinal Chemistry The Use of Bio-Active Compounds of Citrus Fruits as Chemopreventive Agents and Inhibitor of Cancer Cells Viability
Anti-Cancer Agents in Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Cancer Drug Targets Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery